Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
10/16/2003 IDEC Pharmaceuticals Obtains Summary Judgment in Patent Litigation against Corixa and GlaxoSmithKline
10/14/2003 IDEC Pharmaceuticals Reports Third Quarter 2003 Results; Rituxan Sales Increase 31% over Third Quarter 2002 and Earnings Increase to $0.26 Per Diluted Share
10/06/2003 IDEC Pharmaceuticals and Biogen Joint Proxy Statement Cleared by SEC
10/03/2003 IDEC Pharmaceuticals Corporation Third Quarter 2003 Earnings Conference Call
09/23/2003 IDEC Pharmaceuticals to Make Presentation at UBS Warburg Global Life Sciences Conference
09/04/2003 IDEC Pharmaceuticals to Make Presentation at Bear Stearns & Co. 16th Annual Healthcare Conference
09/03/2003 IDEC Pharmaceuticals to Make Presentation at UBS Warburg Global Life Sciences Conference
08/07/2003 IDEC Pharmaceuticals and Biogen Announce U.S. Federal Trade Commission Clearance of Merger
07/17/2003 IDEC Pharmaceuticals Reports Second Quarter 2003 Results
07/16/2003 IDEC Pharmaceuticals Announces Second Quarter 2003 Financials Conference Call
06/23/2003 Biogen and IDEC Pharmaceuticals Announce Merger To Create a New Biotechnology Industry Leader
06/06/2003 IDEC Pharmaceuticals to Make Presentation at Goldman Sachs Annual Global Healthcare Conference
06/01/2003 Zevalin Therapeutic Regimen Produces Durable, Complete Responses in Patients with Non-Hodgkin’s Lymphoma; Zevalin Also Safe and Effective as Second- or Third-Line Therapy
05/16/2003 IDEC Pharmaceuticals Announces Webcast of Its Annual Meeting
05/06/2003 IDEC Pharmaceuticals to Make Presentation at Deutsche Bank 28Th Annual Healthcare Conference
04/30/2003 IDEC Pharmaceuticals to Make Presentation At Morgan Stanley Healthcare Unplugged Conference
04/15/2003 IDEC Pharmaceuticals Reports First Quarter 2003 Results; Rituxan Sales Increase 32% Over First Quarter 2002 and Earnings Increase to $0.24 Per Diluted Share
04/11/2003 IDEC Pharmaceuticals Announces First Quarter 2003 Financials Conference Call
03/20/2003 IDEC Pharmaceuticals to Make Presentation at Banc of America Healthcare Conference
03/17/2003 IDEC Pharmaceuticals to Make Presentation at S.G. Cowen 23rd Annual Health Care Conference
02/25/2003 IDEC Pharmaceuticals Brings Patent Infringement Suit against Corixa and GlaxoSmithKline Concerning Bexxar
01/30/2003 IDEC Pharmaceuticals and Biogen Announce Oncology Collaboration
01/15/2003 IDEC Pharmaceuticals Announces Net U.S. Rituxan Sales for 2002: $318.2 Million in Fourth Quarter and $1.08 Billion for the Full Year
01/03/2003 IDEC Pharmaceuticals Reports Fifth Consecutive Year of Profitability With Earnings Per Share Increasing to $0.85 Per Diluted Share and Revenue Growth of 48 Percent in 2002